Lineage-specific targeting of MYC in these diseases could potentially be achieved by taking advantage of these enhancer regions, as is currently being pursued, for example, in sickle cell disease by targeting an erythroid-specific enhancer of BCL11A40,41. This evidence concerns the gene MYC and sickle cell disease.